Medseven Healthcare

“Our principle is to help our target market look and feel better in every aspect possible by building a healthy environment.” With presence over the course of four decades in United Arab Emirates, our board of directors at MEDSEVEN has excelled in Retail Pharmacy Industry. MEDSEVEN is a leading distribution company in UAE supplying Medical, Pharmaceutical and Generic and Cosmetic products over 135 target Retail Pharmacies in the industry. The company which is incorporated from seven pharmaceutical tycoons has its portfolio over 2500 products from Medical Supplies to imported generic items mostly from EU, North America, Australia and Asia. We’re in addition expanding and serving UAE market with our own product establishment known as Medseven One.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

BIOTECH STARTUP MEKONOS RAISES OVERSUBSCRIBED $25 MILLION ROUND TO OVERCOME PHARMA INDUSTRY'S CELL & GENE THERAPY DELIVERY HURDLES

Mekonos, Inc. | November 10, 2021

news image

Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New institutional and strategic investors, including Section 32, Sands Capital, TDK Ventures, and the venture arm of Debiopharm, and previous investors, including Novartis Pharma AG (dRx Capital) and Elementum Ventures, also joined in the funding round that will...

Read More

EPIGENTEK LAUNCHED FIRST-OF-ITS-KIND TOOLS TO DETECT SARS-COV-2-TARGETED FURIN ACTIVITY AND SCREEN FOR INHIBITORS AGAINST COVID-19

EpiGentek | July 10, 2020

news image

New York-based biotechnology firm EpiGentek has released a series of SARS-CoV-2 research assays in combatting the ongoing COVID-19 pandemic. The two kits focus on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity. These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins. Subsequent implications can be the...

Read More

MEDICAL

MODERNA ANNOUNCES SUPPLY AGREEMENT WITH UK GOVERNMENT FOR ADDITIONAL 2 MILLION DOSES OF MRNA-1273, MODERNA’S VACCINE CANDIDATE AGAINST COVID-19

Moderna | November 30, 2020

news image

Moderna, Inc., a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to make new generation of transformative medicines for patients, today reported a supply agreement with the UK government for an extra 2 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to the United Kingdom starting in March 2021. The UK government has now made sure about 7 million dosages of mRNA-1273. This confirmation comes as the UK proceeds with its efforts to ...

Read More

RESEARCH

BIO-TECHNE AND CARTERRA INITIATE A CLINICAL RESEARCH COLLABORATION FOR COVID-19 VARIANT ANALYSIS

Bio-Techne Corporation | September 08, 2021

news image

Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening and characterization, today announced a clinical research collaboration studying COVID-19 variants. New variants, such as Delta, can be more easily transmitted and more likely to evade the immune response of vaccinated or previously infected people. To assess immune responses to ...

Read More
news image

CELL AND GENE THERAPY

BIOTECH STARTUP MEKONOS RAISES OVERSUBSCRIBED $25 MILLION ROUND TO OVERCOME PHARMA INDUSTRY'S CELL & GENE THERAPY DELIVERY HURDLES

Mekonos, Inc. | November 10, 2021

Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New institutional and strategic investors, including Section 32, Sands Capital, TDK Ventures, and the venture arm of Debiopharm, and previous investors, including Novartis Pharma AG (dRx Capital) and Elementum Ventures, also joined in the funding round that will...

Read More
news image

EPIGENTEK LAUNCHED FIRST-OF-ITS-KIND TOOLS TO DETECT SARS-COV-2-TARGETED FURIN ACTIVITY AND SCREEN FOR INHIBITORS AGAINST COVID-19

EpiGentek | July 10, 2020

New York-based biotechnology firm EpiGentek has released a series of SARS-CoV-2 research assays in combatting the ongoing COVID-19 pandemic. The two kits focus on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity. These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins. Subsequent implications can be the...

Read More
news image

MEDICAL

MODERNA ANNOUNCES SUPPLY AGREEMENT WITH UK GOVERNMENT FOR ADDITIONAL 2 MILLION DOSES OF MRNA-1273, MODERNA’S VACCINE CANDIDATE AGAINST COVID-19

Moderna | November 30, 2020

Moderna, Inc., a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to make new generation of transformative medicines for patients, today reported a supply agreement with the UK government for an extra 2 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to the United Kingdom starting in March 2021. The UK government has now made sure about 7 million dosages of mRNA-1273. This confirmation comes as the UK proceeds with its efforts to ...

Read More
news image

RESEARCH

BIO-TECHNE AND CARTERRA INITIATE A CLINICAL RESEARCH COLLABORATION FOR COVID-19 VARIANT ANALYSIS

Bio-Techne Corporation | September 08, 2021

Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening and characterization, today announced a clinical research collaboration studying COVID-19 variants. New variants, such as Delta, can be more easily transmitted and more likely to evade the immune response of vaccinated or previously infected people. To assess immune responses to ...

Read More